Home » Topics » Infection, BioWorld Science

Infection, BioWorld Science
RSS

FDA issues EUA for Moderna's mRNA-1273 for COVID-19

Dec. 21, 2020

Soricimed to explore utility of SOR-C13 for COVID-19

Dec. 21, 2020

FDA clears IND for AlloVir's ALVR-106 to treat severe respiratory viral infections

Dec. 18, 2020

Shionogi initiates phase I/II study in Japan with COVID-19 vaccine candidate

Dec. 18, 2020

Abpro initiates phase II/III registrational studies of ABP-300 as treatment of COVID-19

Dec. 17, 2020

First participant dosed in phase I study of TBAJ-587

Dec. 17, 2020

Valneva opens phase I/II study of COVID-19 vaccine candidate VLA-2001

Dec. 16, 2020

First patients enrolled in phase IIb study of rNAPc2 for COVID-19

Dec. 16, 2020

Initiation of first-in-human study of CVB vaccine candidate, PRV-101

Dec. 16, 2020

Positive interim data presented from phase IIb portion of ifenprodil COVID Study

Dec. 16, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...